Literature DB >> 31876871

Double-Session Micropulse Transscleral Laser (CYCLO G6) as a Primary Surgical Procedure for Glaucoma.

Leopoldo Magacho1,2, Francisco E Lima1,3, Marcos P Ávila1,3.   

Abstract

PRéCIS:: Double-session micropulse transscleral laser was an effective and safe treatment strategy for eyes that have not undergone glaucoma surgery previously.
PURPOSE: To evaluate the safety and effectiveness of double-session micropulse transscleral laser (MP3) as a primary treatment modality for glaucoma.
MATERIALS AND METHODS: Patients who underwent MP3 therapy with double sessions in each hemifield, with a follow-up period of at least 6 months, were retrospectively considered. Patients were categorized into 2 groups: GI (no previous glaucoma surgery) and GII (with previous glaucoma surgery). Success was defined by either achieving a final intraocular pressure (IOP) between 6 and 18 mm Hg and an IOP reduction of >20%, or a minimum 50% reduction in the number of glaucoma medications, at the last visit, without any serious complications.
RESULTS: Eighty-four eyes were included in the GI group and 101 in the GII group, with the latter demonstrating relatively higher preoperative IOP (31.1±5.4 vs. 26.2±6.9 mm Hg, P<0.001). Final IOP (14.9±5.2 vs. 13.6±4.1 mm Hg, P=0.06), average MP3 treatment time (358.0±50.7 vs. 362.7±67.8 s, P=0.5), and follow-up duration (10.8±5.1 vs. 12.3±5.4 mo, P=0.06) were similar between the groups. The percentage reduction with regard to glaucoma medication was higher in GI than in GII (49.1±28.8 vs. 38.8±30.1%, P=0.02). GI underwent fewer MP3 procedures than GII (1.2±0.5 vs. 1.5±0.8, P=0.002). No hypotony or phthisis bulbi was observed in GI (1 and 2 in GII, respectively). Procedural success was noted in 92.9% of the cases in GI and 87.1% in GII.
CONCLUSIONS: Double-session MP3 therapy could be considered as a safe and effective procedure to treat glaucoma in eyes that have not undergone any previous glaucoma surgery. Primary eyes achieved a success-rate similar to those with refractory glaucoma with fewer MP3 procedures and fewer glaucoma medications.

Entities:  

Mesh:

Year:  2020        PMID: 31876871     DOI: 10.1097/IJG.0000000000001426

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  6 in total

1.  Comparative efficacy and safety of micropulse transscleral laser cyclophotocoagulation using different duration protocols in eyes with good visual acuity.

Authors:  Oya Tekeli; Helin Ceren Köse
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-07-05       Impact factor: 3.117

2.  MicroPulse Transscleral Laser Therapy Demonstrates Similar Efficacy with a Superior and More Favorable Safety Profile Compared to Continuous-Wave Transscleral Cyclophotocoagulation.

Authors:  Enrico Bernardi; Marc Töteberg-Harms
Journal:  J Ophthalmol       Date:  2022-02-08       Impact factor: 1.909

3.  Changes After a Month Following Micropulse Cyclophotocoagulation in Normal Porcine Eyes.

Authors:  So Min Ahn; Mihyun Choi; Seong-Woo Kim; Yong Yeon Kim
Journal:  Transl Vis Sci Technol       Date:  2021-11-01       Impact factor: 3.283

4.  Estimating the Ideal Treatment Protocol and Success Predictors for Double-session Micropulse Transscleral Laser for Glaucoma Management.

Authors:  Leopoldo Magacho; Francisco E Lima; Marcos P Ávila
Journal:  J Curr Glaucoma Pract       Date:  2022 May-Aug

5.  Ciliochoroidal effusion and its association with the outcomes of micropulse transscleral laser therapy in glaucoma patients: a pilot study.

Authors:  Sunee Chansangpetch; Natnaree Taechajongjintana; Kitiya Ratanawongphaibul; Rath Itthipanichpong; Anita Manassakorn; Visanee Tantisevi; Prin Rojanapongpun; Shan C Lin
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

6.  Topical Anesthesia Offers Sufficient Pain Control for MicroPulse Transscleral Laser Therapy for Glaucoma.

Authors:  Belgin Vasella; Marc Töteberg-Harms
Journal:  J Ophthalmol       Date:  2022-09-21       Impact factor: 1.974

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.